Literature DB >> 10027335

A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix.

S Nakagawa1, H Yoshikawa, M Kimura, K Kawana, K Matsumoto, T Onda, N Kino, M Yamada, T Yasugi, Y Taketani.   

Abstract

To investigate involvement of an aberrant expression of the FHIT (fragile histidine triad) gene in the process of carcinogenesis and progression in cervical carcinoma, we examined its expression by the reverse transcriptase polymerase chain reaction (RT-PCR) and cDNA sequence method in 32 cervical invasive carcinomas (25 squamous cell carcinomas and seven adeno- or adenosquamous carcinomas) and 18 of its precursor lesions [four low-grade and 14 high-grade cervical intraepithelial neoplasias (CINs)]. We also examined a link between the occurrence of the aberrant expression and human papillomavirus (HPV). We detected the aberrant FHIT transcripts in 11 of 25 (44%) cervical invasive squamous cell carcinomas and in 5 of 14 (36%) high-grade CINs (CIN 2 or 3), whereas they were not found in seven non-squamous type and four low-grade CINs (CIN 1). The alteration patterns of the FHIT gene expression in high-grade CINs were virtually similar to those found in invasive carcinomas, such that the exons 5-7 were consistently deleted associated or unassociated with loss of the exon 4 and/or 8. The incidence of the aberrant expression was not related to the presence of HPV and its type. These data indicate that the aberrant expression of the FHIT gene is observed in precursor lesions of cervical carcinoma as well as invasive carcinomas, with its incidence not increasing with advance of clinical stage. Given the squamous cell type dominant expression, the aberrant expression may play a critical role in the generation of squamous cell carcinoma of the uterine cervix, but not the consequence of the progression of the cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027335      PMCID: PMC2362444          DOI: 10.1038/sj.bjc.6690093

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.

Authors:  D L Greenspan; D C Connolly; R Wu; R Y Lei; J T Vogelstein; Y T Kim; J E Mok; N Muñoz; F X Bosch; K Shah; K R Cho
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

2.  Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.

Authors:  M Fujita; M Inoue; O Tanizawa; S Iwamoto; T Enomoto
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

3.  Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas.

Authors:  K B Choo; K Y Chong
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

4.  Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.

Authors:  A Helland; R Holm; G Kristensen; J Kaern; F Karlsen; C Trope; J M Nesland; A L Børresen
Journal:  J Pathol       Date:  1993-10       Impact factor: 7.996

5.  The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers.

Authors:  M Ohta; H Inoue; M G Cotticelli; K Kastury; R Baffa; J Palazzo; Z Siprashvili; M Mori; P McCue; T Druck; C M Croce; K Huebner
Journal:  Cell       Date:  1996-02-23       Impact factor: 41.582

6.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

7.  Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers.

Authors:  H Yoshikawa; T Kawana; K Kitagawa; M Mizuno; H Yoshikura; A Iwamoto
Journal:  Jpn J Cancer Res       Date:  1991-05

8.  Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.

Authors:  T Crook; K H Vousden
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

9.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

Authors:  K Münger; B A Werness; N Dyson; W C Phelps; E Harlow; P M Howley
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

10.  The role of p53 inactivation in human cervical cell carcinoma development.

Authors:  K Miwa; S Miyamoto; H Kato; T Imamura; M Nishida; Y Yoshikawa; Y Nagata; N Wake
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more
  5 in total

1.  Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer.

Authors:  S Takizawa; S Nakagawa; K Nakagawa; T Yasugi; T Fujii; K Kugu; T Yano; H Yoshikawa; Y Taketani
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

2.  Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma.

Authors:  Kyung-Do Ki; Seon-Kyung Lee; Seo-Yun Tong; Jong-Min Lee; Dong-Hwa Song; Sung-Gil Chi
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

Review 3.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

4.  Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions.

Authors:  G Terry; L Ho; P Londesborough; J Cuzick
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

5.  Analysis of the expression and localisation of a LAP protein, human scribble, in the normal and neoplastic epithelium of uterine cervix.

Authors:  S Nakagawa; T Yano; K Nakagawa; S Takizawa; Y Suzuki; T Yasugi; J M Huibregtse; Y Taketani
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.